Opella Becomes Independent, Targets Leadership in Consumer Health
Opella, formerly Sanofi's consumer healthcare division, has officially become an independent company following a majority stake acquisition by CD&R. The company aims to become a leader in the global over-the-counter (OTC) and vitamin markets.
Opella, previously Sanofi's global business unit for consumer healthcare, has completed its separation from the parent company and is now operating independently. Private equity firm CD&R has acquired a controlling 50.0% stake, while Sanofi retains a significant 48.2% share. Bpifrance holds the remaining 1.8%. This marks a new chapter for Opella, with a stated mission to make everyday health "simply as it should be."
The company positions itself as a pure-play entity in the nearly 190 billion euro global market for over-the-counter (OTC) medicines and vitamins, minerals, and supplements (VMS). Opella aims to leverage long-term trends such as an aging population, digitalization, e-commerce, and growing consumer interest in self-care to drive growth and market leadership.
With a portfolio of 100 brands, including Allegra, Dulcolax, and Enterogermina, Opella employs 11,000 people worldwide and operates 13 manufacturing sites. The company, headquartered in France, seeks to simplify daily healthcare access for consumers who, according to Opella, often find the current environment too complex.
Under the leadership of CEO Julie Van Ongevalle and new supervisory board chairman David Taylor, formerly CEO of Procter & Gamble, Opella is focused on strengthening brand trust and expanding its presence in strategic markets. The company also indicates openness to targeted acquisitions and geographic expansion as it seeks to redefine the consumer health landscape.